SenzaGen AB (OM: SENZA)
Health Care · Biotechnology · SE
Skr4.56
+1.10% today · -23.5% 1Y
SenzaGen AB (OM: SENZA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $14.97M and employs 34 people.
Over the last twelve months the share price has lost 23.5%, trading between 4.26 and 6.84.
Tweenvest scores SenzaGen AB across four factors: quality 58/100, value 73/100, growth 74/100. Its strongest factor is growth.
SENZA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $14.97M
- Revenue (TTM)
- $6.30M
- P/E
- —
- EPS
- -0.31
- Dividend yield
- —
- Beta (5Y)
- 0.60
- 52-week high
- Skr6.84
- 52-week low
- Skr4.26
- Avg volume (3M)
- —
- Shares outstanding
- 32.51M
- Employees
- 34
- Next earnings
- —
About SenzaGen AB
SenzaGen AB specializes in pioneering, conducting, and commercializing animal-free methods to evaluate the allergic potential of various substances. Their product portfolio encompasses several in vitro tests: GARDskin identifies potential chemical skin sensitizers; GARDpotency, an enhancement to GARDskin, categorizes their strength; GARDskin Dose-response delivers precise quantitative assessment of skin sensitizing potency; and GARDair detects chemical respiratory sensitizers. They also offer GARDskin medical device for assessing skin sensitization caused by medical equipment and solid materials. Furthermore, the company provides services for irritation and corrosion analysis. SenzaGen distributes its solutions through a network of licensed partners and distributors. The firm also collaborates with the Research Institute for Fragrance Materials to develop novel photosensitization tests. Founded in 2010, the company's headquarters are located in Lund, Sweden.
- ISIN
- SE0010219626
- Founded
- 2010
- Listed since
- Sep 21, 2017
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Biotechnology Assets, S.A.BME: BST | $15.35M | €0.18 | -4.70% |
| Xcell Therapeutics Inc.KOSDAQ: A373110 | $15.16M | ₩1,169.00 | +9.87% |
| Read-Gene S.A.WSE: RDG | $15.06M | zł4.96 | -1.59% |
| Dyadic International, Inc.NasdaqCM: DYAI | $14.98M | $0.41 | -7.43% |
| Valbiotis SAENXTPA: ALVAL | $14.66M | €0.55 | +3.36% |
| Poongjeon Pharmacy CO.,LTD.KOSDAQ: A298060 | $14.56M | ₩2,195.00 | -5.39% |
| Actuate Therapeutics, Inc.NasdaqGM: ACTU | $14.53M | $0.61 | -0.85% |
| Initiator Pharma A/SOM: INIT | $14.45M | Skr2.09 | +16.11% |
Figures last refreshed Oct 18, 2026.